PBYI - Puma Biotechnology, Inc.
| Previous Close | 62.35 |
| Open | 62.15 |
| Bid | 61.00 x 100 |
| Ask | 65.50 x 200 |
| Day's Range | 60.85 - 62.90 |
| 52 Week Range | 28.35 - 136.90 |
| Volume | 420,313 |
| Avg. Volume | 987,758 |
| Market Cap | 2.31B |
| Beta | 1.67 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.86 |
| Earnings Date | May 8, 2018 - May 14, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 96.00 |
- Business Wire•18 days ago
Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Puma Biotechnology, Inc. , a biopharmaceutical company, and Pint Pharma International S.A., a company focused on innovative treatments for patients in Latin America with cancer, rare diseases, and genetic disorders, have entered into an agreement for Pint Pharma to commercialize NERLYNX® in Argentina, Brazil, Chile, Colombia, Mexico and the rest of Latin America.
- Zacks•19 days ago
Puma's Shares Fall This Year Post a Solid 2017: Here's Why
Although the FDA approval for Puma's (PBYI) Nerlynx along with strategic alliances appreciates the stock in 2017, the CHMP's negative opinion on the cancer drug in 2018 affects its share price.
- Business Wire•19 days ago
NCCN Guidelines for Central Nervous System Cancers Include NERLYNX® (neratinib) in Combination With Capecitabine or Paclitaxel as Treatment Options for Patients With Breast Cancer Brain Metastases
Puma Biotechnology, Inc. , a biopharmaceutical company, announced today that NERLYNX® has been included as a recommended treatment option in the latest National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology Central Nervous System Cancers for Breast Cancer patients with brain metastases.
- Zacks•19 days ago
Puma Biotechnology (PBYI) Up 10.2% Since Earnings Report: Can It Continue?
Puma Biotechnology (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.•23 days ago
Puma Biotechnology Inc (NASDAQ:PBYI) Is Trading At A 47% Discount
I am going to run you through how I calculated the intrinsic value of Puma Biotechnology Inc (NASDAQ:PBYI) using the discounted cash flow (DCF) method. Anyone interested in learning aRead More...
- Business Wire•24 days ago
Robbins Geller Rudman & Dowd LLP Announces Pending Class Action in the Puma Biotechnology, Inc. Litigation
The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Puma Biotechnology, Inc. Litigation:
- Simply Wall St.•last month
Does Puma Biotechnology Inc’s (NASDAQ:PBYI) -5.79% Earnings Drop Reflect A Longer Term Trend?
Examining Puma Biotechnology Inc’s (NASDAQ:PBYI) past track record of performance is a valuable exercise for investors. It enables us to understand whether the company has met or exceed expectations, whichRead More...
- Business Wire•2 months ago
Puma Biotechnology to Present at Cowen’s Annual Healthcare Conference
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 11:20 a.m.
- Motley Fool•2 months ago
Why Puma Biotechnology Shares Jumped 15% Today
Management delivered good news to investors about sales of its breast cancer drug, Nerlynx.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of PBYI earnings conference call or presentation 1-Mar-18 9:30pm GMT
Q4 2017 Puma Biotechnology Inc Earnings Call
- Zacks•2 months ago
Puma (PBYI) Q4 Loss Narrower Than Expected, Shares Down
Puma (PBYI) posts narrower-than-expected loss in Q4. Revenues also surpass estimates supported by sales of the company's only marketed drug, Nerlynx.
- Associated Press•2 months ago
Puma Biotech reports 4Q loss
The Los Angeles-based company said it had a loss of $1.71 per share. Losses, adjusted for stock option expense, were $1.03 per share. The results topped Wall Street expectations. The average estimate of ...
- Business Wire•2 months ago
Puma Biotechnology Reports Fourth Quarter and Full Year 2017 Financial Results
Puma Biotechnology, Inc. , a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2017. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2017, compared to the fourth quarter and full year 2016.
- ACCESSWIRE•2 months ago
Puma Biotechnology, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 1, 2018 / Puma Biotechnology, Inc. (NASDAQ: PBYI ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 1, 2018 at 4:30 PM Eastern Time. ...
- ACCESSWIRE•2 months ago
Blog Exposure - CHMP Recommended Against Approval of Puma Biotech's Neratinib for Extended Adjuvant Treatment of HER2-Positive Breast Cancer
Stock Monitor: BioMarin Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 27, 2018 / Active-Investors.com has just released a free research report on Puma Biotechnology, Inc. (NASDAQ: PBYI ...
- Market Exclusive•2 months ago
Here’s What’s Moving KemPharm And Puma Biotechnology
KemPharm, Inc. (NASDAQ:KMPH) ran into the end of last week on news related to the company’s lead development program. At the close of trade on Friday, KemPharm shares were going for around six dollars apiece, up more than 13% on the day’s open. Premarket on Monday, shares rose again to $6.35 but have since settled […] The post Here’s What’s Moving KemPharm And Puma Biotechnology appeared first on Market Exclusive.
- Business Wire•2 months ago
Puma Biotechnology Receives Results of CHMP Formal Decision for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Puma Biotechnology, Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a negative opinion, recommending the refusal of the Marketing Authorisation Application for neratinib for the extended adjuvant treatment of early stage HER2-positive breast cancer.
- GlobeNewswire•2 months ago
New Research Coverage Highlights SunCoke Energy Partners, Carrols Restaurant Group, First Financial, Emerson Electric, Puma Biotechnology, and Amgen — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Feb. 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SunCoke ...
- Business Wire•2 months ago
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results
Puma Biotechnology, Inc. , a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, March 1, 2018 following release of its fourth quarter and full year 2017 financial results.
- ACCESSWIRE•2 months ago
Today’s Research Reports on Trending Tickers: Nektar Therapeutics and Puma Biotechnology
NEW YORK, NY / ACCESSWIRE / February 15, 2018 / U.S. markets rallied sharply from early losses Wednesday as inflation fears appear to be easing on Wall Street. The Dow Jones Industrial Average jumped 1.03 ...
- Business Wire•2 months ago
Puma Biotechnology to Present at LEERINK Partners Global Healthcare Conference
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 3:30 p.m.
- Zacks•3 months ago
Puma, CANbridge Team Up to Commercialize Nerlynx in China
Puma (PBYI) enters an exclusive agreement with CANbridge under which the latter will seek regulatory approval for Nerlynx in China and develop and commercialize it in the region.
- Business Wire•3 months ago
Puma Biotechnology and CANbridge Life Sciences Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Greater China
Puma Biotechnology, Inc. , a biopharmaceutical company, and CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, have entered into an exclusive agreement under which CANbridge will develop and commercialize NERLYNX® in mainland China, Taiwan, Hong Kong, and Macau .
- Business Wire•3 months ago
Puma Biotechnology Announces Publication of Results from Phase II SUMMIT ‘Basket’ Trial Evaluating Neratinib in HER2 and HER3 Mutant Cancers
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that initial results from the company’s ongoing SUMMIT Phase II ‘basket’ clinical trial of PB272 in patients with tumors harboring HER2 or HER3 mutations were published in the journal Nature.
- Zacks•3 months ago
Puma & Medison Team Up to Commercialize Nerlynx in Israel
Puma (PBYI) and Medison enters into a licensing deal to commercialize Puma's breast cancer treatment drug Nerlynx in Israel.
